Luanhaixin (Talk | contribs) |
Luanhaixin (Talk | contribs) |
||
| Line 41: | Line 41: | ||
height: 100% !important; | height: 100% !important; | ||
} | } | ||
| + | body{ | ||
| + | height:100% !important; | ||
| + | } | ||
.word { | .word { | ||
Vulvovaginal candidiasis (VVC) has been recognized as one of the most common infections in female reproductive organs. VVC is mainly caused by Candida albicans (C. albicans), accounting for more than 85% of the incidence, which seriously affects the normal life of women. 70-75% of women will suffer from VVC at least once in thier life time. 40-45% will have 2 or more episodes. Abnormal Vaginal Discharge Genital and Vaginal burning External Dysuria Itching and Redness Till now, as a commonly used antifungal drug for VVC treatment, vaginal azole preparations can inhibit the growth of C. albicans, or kill them directly.
What's VVC?
Symptoms
How to Treat?
HOWEVER
The widespread usage of antifungal drugs and the increase in the number of fungal infections have led to the emergence of drug resistance, even the repeated recurrence to VVC of patients.
But, there is a
New Therapy for Vulvovaginal Candidasis:
Sensing system can sense C. albicans and activate the downstream gene.
LL37 can perforate the cell membrane of C.albicans.
The β-1,3-glucanase can disrupt the biofilm of C. albicans.
BDSF can inhibit hypha formation by C. albicans.
Msp1 can destabilize the hyphae of C. albicans.
Our project is well conducted by Model in terms of experiments and prediction of future application. Our Model is constituted with1. C. albicans Sensing Model2. Gene Concentration Prediction Model3. Market Prediction Model